(Q34865832)

5 August 2017

1 reference

title

Proton pump inhibitors--differences emerge in hepatic metabolism (English)

1 reference

5 August 2017

McColl KE

1

1 reference

5 August 2017

Kennerley P

series ordinal

2

1 reference

5 August 2017

publication date

1 July 2002

1 reference

Digestive and Liver Disease

5 August 2017

published in

1 reference

5 August 2017

volume

34

1 reference

5 August 2017

issue

7

1 reference

5 August 2017

page(s)

461-467

1 reference

Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Phenotyping polymorphic drug metabolism in the French Caucasian population

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Safety profile of the proton-pump inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

A prospective follow-up study of 5669 users of lansoprazole in daily practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

The clinical safety of omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Safety experience from long-term treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Safety profile of Lansoprazole: the US clinical trial experience

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980102-5

7 January 2021

10.1016/S1590-8658(02)80102-5

Identifiers

DOI

1 reference

5 August 2017

1 reference